Summary of LB Pharmaceuticals Conference Call Company Overview - **Company**: LB Pharmaceuticals (NasdaqGM:LBRX) - **Event**: 2026 Conference on March 11, 2026 - **CEO**: Heather Turner Key Points Financial Performance - LB Pharmaceuticals raised **$300 million** in its IPO and an additional **$100 million** through a PIPE last month, fully funding the expansion into three programs [9][10] Product Development: LB-102 - **LB-102** is a new chemical entity developed to improve upon amisulpride, a widely used antipsychotic with poor blood-brain barrier permeability [15][16] - LB-102 has shown **70% dopamine receptor occupancy** at a **50 mg** dose and **80%** at **100 mg**, indicating potential efficacy in treating schizophrenia [23][24] - The company plans to conduct a **Phase 3 trial** with both **50 mg** and **100 mg** doses, following statistically significant results in a Phase 2 trial [25][28] Clinical Trial Insights - The Phase 2 trial demonstrated a clinically meaningful reduction in PANSS total scores, moving patients from acute schizophrenia to a stabilized state [30] - The baseline PANSS score was **94**, with a reduction of **14-16 points**, indicating significant improvement [40] - The placebo rate was managed effectively, with a placebo score of **9.3** [41] Safety and Adverse Events - LB-102 exhibited a low rate of extrapyramidal symptoms (EPS), with **5.6%** at the **100 mg** dose, compared to amisulpride's rates in the teens [48] - Prolactin increase was observed but did not lead to discontinuation, with rates between **1%-5.6%** [48] - Anxiety and insomnia were reported, but these were not significantly different from placebo [49] Future Trials and Indications - The Phase 3 trial for schizophrenia is set to start this month, targeting **460 patients** across **25 sites** in the U.S., with data expected in the second half of **2027** [61][59] - LB-102 is also being explored for **bipolar depression**, with a Phase 2 trial initiated earlier this quarter, targeting **25 mg** and **50 mg** doses [81][93] - An adjunctive MDD trial is planned, leveraging the safety data from schizophrenia trials, with a target of **380 patients** and data expected in the first half of **2029** [126][128] Commercial Strategy - The company is preparing for a potential launch in schizophrenia, with a focus on developing evidence for value dossiers and commercial positioning [136][143] - A chief commercial officer has been appointed to lead these efforts [143] Manufacturing and Long-Acting Injectable (LAI) Potential - LB Pharmaceuticals is working on scaling up clinical supply for commercial launch, with plans for a long-acting injectable formulation, which could open new markets [200][201] Conclusion - LB-102 presents a promising opportunity to address unmet needs in schizophrenia and other mood disorders, particularly in cognition and anhedonia, which are significant challenges in these patient populations [221]